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Background
There are no prospective studies comparing the effec-
tiveness of the three iron chelators commercially avail-
able in preventing or decreasing iron overload in the
heart in pediatric thalassemia major (TM) patients. Our
aim was to evaluate the changes in cardiac iron and
function by quantitative magnetic resonance imaging
(MRI) over a follow-up (FU) of 18 months in pediatric
TM patients treated with one of the 3 available iron
chelators in monotherapy or non-chelated.
Methods
Among the first 1611 TM patients enrolled in the
MIOT (Myocardial Iron Overload in Thalassemia) net-
work, we considered pediatric patients who had main-
tained the same chelation regimen between the two
MRI scans. Myocardial iron overload (MIO) was quanti-
fied by a multislice multiecho T2* sequence. Biventricu-
lar function parameters were evaluated by cine images.
Due to the low sample size, no inter-treatment compari-
sons were performed.
Results
Four groups of patients were identified: 6 patients (3 F,
10.0±2.2 years) treated with desferioxamine (DFO- mean
dosage 43.7±6.8 mg/kg/die), 7 patients (3 F, 15.5±1.7 yrs)
treated with deferiprone (DFP- mean dosage 75.0±9.2 mg/
kg/die), 39 patients (13 F, 13.58±3.39 yrs) treated with
deferasirox (DFX- mean dosage 26.6±6.7 mg/kg/die), and
2 patients (2 F, 11.1±5.3 yrs) not chelated because they
had performed a bone marrow transplantation.
Compliance to chelation therapy was excellent/good in all
treated groups.
At baseline in DFO, DFP and no chelated groups no
patient showed a global heart T2* value<20 ms. In all 4
groups all patients who showed no cardiac iron overload
at baseline maintained at the FU the same status. At
baseline in DFX group 5 patients had heart T2*
values<20 ms. The 4 patients with intermediate cardiac
iron (T2* 10-20 ms) at the baseline showed no iron at
the FU while the patient with severe cardiac iron
(T2*<10 ms) remained in the same status at the FU.
Non chelated patients had higher global heart T2*
values at baseline (non-chelated 37.7±0.5 ms > DFP 35.3
±4.9 ms > DFX 32.7±9.6 ms > DFO 31.9±10.5 ms) while
DFP patients had higher global heart T2* values at FU
(DFP 39.5±6.1 ms > DFX 34.2±7.3 ms > DFO 33.6±7.9
ms > non-chelated 28.9±4.0 ms).
In the DFO group at baseline 1 patient showed patho-
logical left ventricular ejection fraction (LVEF) and he
recovered at the follow up. In the DFP group at baseline
2 patients showed pathological LVEF and both recov-
ered at the follow up. In the DFX group at baseline 3
patients showed pathological LVEF: 2 recovered at the
FU and 1 did not perform the evaluation of the cardiac
function at FU due to technical reasons. Conversely 9
patients with normal LVEF at baseline showed patholo-
gical LVEF at the FU.
Conclusions
In this young population, DFP and DFO seem to be
more effective versus the cardiac iron with a concordant
positive effect on the global systolic function. However,
further prospective studies are needed on larger study
population to confirm the data.
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